AssetMemo
AssetsMechanismsCompaniesCalendarChartsWatchlistAsk AIMethodology
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
◧AssetMemo
⌕

Evidence-graded drug-asset intelligence
◧AssetMemo
AssetsMechanismsCompaniesReadout CalendarCompare ChartsWatchlist & AlertsAsk AI
Therapeutic areas
  • Cardiovascular & Metabolic469
  • Dermatology230
  • Gastroenterology & Hepatology177
  • Hematology45
  • Immunology176
  • Infectious Disease145
  • Nephrology130
  • Neurology478
  • Oncology1,186
  • Ophthalmology75
  • Psychiatry141
  • Rare & Genetic Diseases141
  • Respiratory162
ReferenceMethodology & RubricUs vs. AI ToolsUK IBD Access GuideAbout the founder

Educational data tool. Evidence graded; securities never are.

BrowseAll assetsAll mechanismsAll companiesReadout calendarReadouts by yearResults by diseaseDelayed readoutsOpen dataCompare share pricesWhat's new
ReferenceMethodology & sourcesUs vs. the AI toolsUK IBD Access GuideAbout the founderAsk the AIReport a problem / suggest a feature

Educational research only, not investment advice. Evidence quality is graded; securities never are. · Terms · Privacy · Logos by Logo.dev

Ask

Opening the console…

A lane for every drug and company you follow

What changed in the last 30 days and what is due in the next 90, on one timeline, with a daily or weekly email. A free account follows up to 5 items.

Create a free accountSign in

Example, from today's data
22 OctToday21 Dec20 Jan19 Feb
CompanyAbivaxnext in 10d
20 Nov 2026 · NewsAbivax Statement on Short Seller Report13 Nov 2026 · Trial update[obefazimod] NCT07453784: Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation9 Nov 2026 · Trial update[obefazimod] NCT05121714: Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX4642 Nov 2026 · NewsAbivax to Participate in Upcoming Fall Investor ConferencesDec 2026 (month only) · in 10d · NCT06456593Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's D...21 Dec 2026 · in 30dAbivax Earnings Call
Drugobefazimodnext in 10d
13 Nov 2026 · Trial updateNCT07453784: Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation9 Nov 2026 · Trial updateNCT05121714: Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464Dec 2026 (month only) · in 10d · NCT06456593Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's D...
Drugadalimumabnext in 0d
19 Nov 2026 · Trial updateNCT06390436: Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis12 Nov 2026 · Trial updateNCT07845604: Precision Depression Adalimumab Trial12 Nov 2026 · Trial updateNCT07904780: Withdrawal Versus Continued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile Idiopathic Arthritis9 Nov 2026 · Trial updateNCT07788807: A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon9 Nov 2026 · Trial updateNCT06996652: An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)9 Nov 2026 · Trial updateNCT07913750: Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation7 Nov 2026 · NewsNew Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System7 Nov 2026 · NewsNovember 7, 2026 - New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System4 Nov 2026 · NewsBiora Therapeutics Receives Approval for First-in-Human Trial of BioJet™ Oral Biologic Delivery Capsule2 Nov 2026 · Trial updateNCT02706704: Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis27 Oct 2026 · Trial updateNCT07348588: Intravitreal Adalimumab in Inherited and Degenerative Retinal Diseases26 Oct 2026 · Trial updateNCT05928039: PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease23 Oct 2026 · Trial updateNCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseNov 2026 (month only) · in 0d · NCT05874505Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uvei...30 Dec 2026 · in 39d · NCT07398651Apremilast and Adalimumab in Psoriatic Arthritis Patients31 Dec 2026 · in 40d · NCT05105347Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory...Jan 2027 (month only) · in 41d · NCT03153319Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI1 Jan 2027 · in 41d · NCT05535738Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationFeb 2027 (month only) · in 72d · NCT06972446A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Trial updateNewsFinancialsPipelineReadout dueEarnings dueMonth only